STRIDE-1: A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects With Treatment Resistant Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Bupropion/dextromethorphan (Primary)
- Indications Depression
- Focus Therapeutic Use
- Acronyms STRIDE-1
- Sponsors Axsome Therapeutics
- 07 Mar 2017 According to an Axsome Therapeutics media release, top-line results from this study are expected in 1Q 2018.
- 14 Feb 2017 According to an Axsome Therapeutics media release, the US FDA has granted Fast Track Designation for AXS-05 for the treatment of resistant depression.
- 17 Mar 2016 Status changed from planning to recruiting, according to an Axsome Therapeutics media release.